



















































































































































































































































































































Biennial	 Meeting	 In	 Conjunction	 with	 ANS,	 Poster	 Presentation,	 August	 2015,	 Cairns,	
Australia	
	







Plummer	 SL,	 Thornton	 E,	 Corrigan	 F,	 Vink	 R,	 Cappai	 R	 and	 Van	 Den	 Heuvel	 C,	 Florey	
International	 Postgraduate	 Research	 Conference,	 Poster	 Presentation,	 September	 2014,	
Adelaide,	Australia	
	






































































































of	 this	 research,	 and	 have	 sacrificed	 their	 lives	 for	 the	 benefit	 of	 human	 scientific	
advancement.	Without	them,	the	progression	of	this	work	would	not	have	been	possible,	and	





























































following	 TBI.	 Recently,	 the	 APP	 derivative	 APP96 110,	 a	 15	 amino	 acid	 length	 peptide	
derivative,	has	continued	to	display	these	neuroprotective	and	neurotrophic	functions.	While	
the	 mechanisms	 for	 this	 remain	 unclear,	 it	 is	 hypothesized	 that	 these	 neuroprotective	
properties	are	linked	to	its	ability	to	bind	to	heparin,	and	that	these	regions	are	responsible	
for	 the	 protection	 against	 neuronal	 injury	 and	 the	 improvement	 in	 neurological	 outcome	
following	 TBI.	 In	 order	 to	 further	 develop	 APP96 110	 as	 a	 novel	 and	 clinically	 relevant	
therapeutic	agent	following	TBI,	it	was	essential	to	determine	the	optimal	dose,	route	of	and	




rats	 that	was	 the	 first	 to	 assess	 the	 efficacy	 of	 intravenous	 (IV)	 APP96 110	 acutely	 at	 30	
minutes	post TBI,	followed	by	the	more	clinically	relevant	5	hour	timepoint.	IV	administration	
of	 APP96 110	was	 shown	 to	 be	 neuroprotective	 for	 up	 to	 5	 hours	 post TBI,	with	 animals	
demonstrating	 improvements	 in	motor	 outcome	 and	 reductions	 in	 axonal	 injury	 (AI)	 and	
neuroinflammation	when	treated	with	the	highest	dose.	Studies	also	assessed	the	ability	to	
generate	APP	analogues	with	alterations	to	the	amino	acid	sequence,	to	enhance	the	heparin	
binding	 affinity	 of	 the	 peptide,	 and	 examine	 whether	 this	 translated	 to	 increased	
	 	 	
	 	 xviii	
neuroprotection	 following	TBI.	Mutation	of	 the	APP96 110	peptide	to	enhance	 its	heparin	
binding	affinity	resulted	in	a	peptide	with	a	stronger	affinity	for	heparin	(3+APP96 110),	and	
in	vivo,	resulted	in	smaller	doses	conferring	equal	neuroprotective	action	to	higher	doses	of	
wildtype	(WT)	APP96 110	post TBI.	 In	addition,	 the	 long term	efficacy	of	 these	APP96 110	
derivatives	was	examined,	with	emphasis	placed	on	assessing	long term	functional	outcome,	
and	 beginning	 to	 elucidate	 the	 long term	 neuroinflammatory	 and	 neurodegenerative	
changes.	Assessment	of	the	long term	efficacy	demonstrated	that,	whilst	WT	and	3+APP96
110	 produced	 similar	 protection	 for	 neuroinflammation,	 axonal	 structure,	 myelination,	









































































TBI	 is	 a	 life threatening	 injury,	 and	 yet	 despite	 its	 serious	 nature,	 there	 are	 currently	 no	
effective	 therapeutic	 agents	 to	 treat	 the	 condition.	 The	 following	 research	 examines	 the	
neuroprotective	role	of	the	APP96 110	peptide	following	TBI,	with	the	goal	of	progressing	the	
pre clinical	 development	 of	 this	 peptide	 as	 a	 novel	 therapeutic	 agent.	 This	 was	 achieved	
through	the	assessment	of	intravenous	delivery	as	a	viable	route,	determining	the	optimal	
timepoint	of	administration,	the	development	of	novel	analogues	with	enhanced	therapeutic	








































Harlan	 strain.	These	differences	 include	differences	 in	growth	 rate	and	body	composition,	
including	a	higher	body	fat	mass,	higher	gross	liver	weight,	lower	testicular	weight	and	lower	









The	 induction	 of	 anaesthesia	 was	 conducted	 using	 isoflurane.	 Animals	 were	 placed	 in	 a	
transparent	plastic	 induction	 chamber	with	 isoflurane	delivered	at	5%	 in	1.4L/min	N2	and	
0.6L/min	O2	for	5	minutes.	Animals	were	 intubated	with	a	16G	x	2”	 sized	 IV	 catheter	 and	





TBI	 was	 induced	 using	 the	 impact acceleration	 model	 of	 diffuse	 axonal	 injury	 (DAI)		






and	bregma	 sutures.	Animals	were	placed	on	a	 foam	bed	of	10cm	height,	 and	 injured	by	
releasing	a	450g	weight	from	2	metres	onto	the	metallic	disk	(Marmarou	et	al.,	1994)	(Figure	
2.1).	This	produces	widespread	damage	to	axons,	particularly	in	white	matter	tracts	of	the	
brain.	 Directly	 following	 injury,	 animals	 received	 10	 minutes	 of	 hypoxia	 (2L/min	 N2	 and	










Australia)	and	were	all	N terminally	acetylated	and	C terminally	amidated	 (see	Table	2.1).	
Peptides	were	 received	 as	 lyophilized	 powder	 and	dissolved	 in	 distilled	water	 to	 produce	






































are	 trained	 daily	 on	 the	 rotarod	 for	 4 5	 days	 prior	 to	 injury	 until	 they	 can	 complete	 120	
seconds	to	ensure	an	even	baseline	for	all	treatment	groups.	The	length	of	time,	in	seconds,	

























Y Maze	 Day	5	&	Day	23	 Hippocampal	dependent	spatial	&	
recognition	memory	
Barnes	Maze	 Days	24,	25,	26	&	28	 	












2.7).	The	 time	spent	 swimming	versus	 immobility/floating	was	 recorded.	Rats	displaying	a	

























At	 pre determined	 time points	 post TBI,	 animals	 were	 anaesthetised	 with	 5%	 isoflurane	
(2L/min	of	O2)	of	isoflurane	for	3	minutes.	Upon	the	absence	of	pain	reflexes,	the	heart	was	
exposed,	 and	 arterial	 blood	 was	 taken	 from	 the	 aorta.	 Animals	 were	 then	 transcardially	
perfused	 with	 sodium	 chloride	 solution	 (Baxter).	 Brains	 were	 extracted	 immediately	 and	
dissected	to	remove	the	left	and	right	frontal	cortex,	the	corpus	callosum	and	the	left	and	








Histological	 analysis	 of	 brain	 tissue	 in	 Chapters,	 4,	 5	 and	 6	 was	 undertaken	 using	






followed	 by	 antigen	 detection	with	 3,3' Diaminobenzidine	 tetrahydrochloride	 (DAB)	 for	 7	
minutes,	 and	 sections	 counterstained	with	 haematoxylin.	 Sections	 were	 digitally	 scanned	
using	the	Nanozoomer	slide	scanner	(Hamamatsu,	Hamamatusu	City,	Shizuoka,	Japan),	and	






















































iBlot	 2	 Dry	 Blotting	 System	 in	 accordance	 with	 the	 manufacturer’s	 instructions	 (Life	
Technologies).	Membranes	were	stained	with	Ponceau	S	red	solution	(Fluka	Analytical)	for	2	
minutes	for	visual	inspection	to	ensure	equal	protein	loading	in	each	well.	Membranes	were	





with	 the	 primary	 antibodies	 and	 housekeeper	 protein,	 which	 were	 used	 at	 individually	
optimized	 concentrations	 (refer	 to	 table	 2.4).	 Overnight	 incubation	was	 undertaken	 on	 a	




















Antibody	 Target	 Brain	Region	 Dilution	 Species	 Manufacturer	
	


















































variance	(ANOVA):	one or two way	or	repeated	measures,	as	necessary,	followed	by	Tukey’s	











injury	 severity	 in	 Sprague Dawley	 (SD)	 rats	 following	 the	 Marmarou	 impact acceleration	
model	of	moderate severe	TBI,	as	measured	by	functional	outcome	tests	and	histology.	This	






























al.,	 2015).	 Studies	 have	 shown	 Charles	 River	 strain	 SDs	 to	 demonstrate	 a	 number	 of	
differences	 to	 other	 strains,	 in	 particular	 Harlan	 strain	 SDs.	 These	 differences	 include	
differences	 in	growth	rate	and	body	composition,	 including	a	higher	body	fat	mass,	higher	
gross	liver	weight,	lower	testicular	weight	and	lower	cholesterol	levels	(Brower	et	al.,	2015).	
Furthermore,	 a	 number	 of	 studies	 have	 demonstrated	 strain	 and	 sub strain	 differences	
between	other	laboratory	rats	like	Wistars	from	different	sources	in	a	number	of	conditions	
including	 status	 epilepticus,	 and	 neurodegeneration	 (Honndorf	 et	 al.,	 2011,	 Langer	 et	 al.,	
2011).	While	these	features	are	not	directly	relevant	to	the	field	of	TBI	research,	it	provides	










were	 purchased	 from	 the	 Animal	 Resources	 Centre	 (ARC)	 in	 Perth,	 Australia	 weighing	




week	of	pre training	 for	motor	assessments,	animals	were	 injured	between	380	and	418g	
using	the	Marmarou	impact acceleration	model	(previously	described	in	Material	&	Methods	














strain	 SDs	 were	 aged	 between	 10 12	 weeks	 for	 injury,	 their	 weights	 at	 this	 age	 differed	
considerably.	Previously	used	Harlan	strain	rats	weighed	approximately	350 380g	at	this	age,	


























While	 physical	 and	 motor	 outcomes	 are	 both	 key	 indications	 in	 injury	 severity	 post TBI,	
histological	analysis	of	AI	 is	fundamental,	with	motor	performance	previously	shown	to	be	
associated	with	the	extent	of	axonal	 injury	post TBI	(Thornton	et	al.,	2006,	Corrigan	et	al.,	
2012a).	Histological	analysis	post TBI	was	assessed	using	 IHC,	with	APP	used	as	marker	 to	
indicate	 axonal	 injury	 (previously	 described	 in	Materials	&	Methods	 Part	 I,	 section	 2.6.1).	














Following	 the	 subsequent	 establishment	 of	 a	 Charles River	 SD	 breeding	 colony,	 a	
comprehensive	 study	was	undertaken	 that	aimed	 to	assess	both	 the	acute	and	 long term	
efficacy	of	IV	APP96 110	following	a	moderate severe	diffuse	TBI.	Animals	were	injured	using	
the	 Marmarou	 impact acceleration	 model	 as	 previously	 described.	 At	 5	 hours	 post TBI,	
animals	were	treated	with	either	saline	vehicle	control,	0.5mg/kg	of	an	AP96 110	analogue	
(previously	shown	to	shown	reduced	efficacy	post TBI)	(Corrigan	et	al.,	2014),	0.25mg/kg	and	
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Figure	 3.5:	 The	 coloured	 protocol	



















derivative	 APP96 110	 have	 shown	 encouraging	 neuroprotective	 activity	 following	 TBI	
following	an	intracerebroventricular	administration.	Nevertheless,	its	broader	clinical	utility	
would	be	enhanced	by	an	intravenous	(IV)	administration.	This	study	assessed	the	efficacy	of	
IV	APP96 110,	where	a	dose response	for	a	single	dose	of	0.005mg/kg	–	0.5mg/kg	APP96 110	
at	either	30	minutes	or	5	hours	following	moderate severe	diffuse	impact acceleration	injury	
was	performed.	Male	Sprague Dawley	rats	were	assessed	daily	for	3	or	7	days	on	the	rotarod	
to	 examine	 motor	 outcome,	 with	 a	 separate	 cohort	 of	 animals	 utilised	 for	
immunohistochemistry	 analysis	 3	 days	 post TBI	 to	 assess	 axonal	 injury	 and	
neuroinflammation.	 Animals	 treated	 with	 0.05mg/kg	 or	 0.5mg/kg	 APP96 110	 after	 30	
minutes	demonstrated	significant	improvements	in	motor	outcome.	This	was	accompanied	
by	a	reduction	in	axonal	injury	(AI)		and	neuroinflammation	in	the	corpus	callosum	at	3	days	
post TBI,	 whereas	 0.005mg/kg	 had	 no	 effect.	 In	 contrast,	 treatment	 with	 0.005m/kg	 or	
0.5mg/kg	APP96 110	at	5	hours	post TBI	demonstrated	significant	 improvements	 in	motor	
outcome	over	3	days,	which	was	accompanied	by	a	reduction	in	axonal	injury	in	the	corpus	
callosum.	This	demonstrates	that	APP96 110	remains	efficacious	for	up	to	5	hours	post TBI	







Traumatic	 brain	 injury	 (TBI)	 is	 a	major	 public	 health	 concern,	 one	which	 in	 industrialised	
countries	leads	to	more	deaths	in	people	under	the	age	of	45	than	any	other	cause	(Feigin	et	






axonal	 injury	 (DAI),	 a	 significant	 feature	 of	 TBI,	 is	 the	most	 common	 cause	 of	 coma	 and	
vegetative	state	following	head	trauma	(Adams	et	al.,	1989,	Smith	et	al.,	2003).	Occurring	as	
a	 result	of	 rapid	acceleration/deceleration	 forces,	DAI	causes	considerable	deformation	of	
brain	 tissue	 through	 shearing	 forces	 and	 stretching,	 and	 currently	 lacks	 an	 efficacious	
pharmacological	treatment.	Many	of	these	serious	events	could	be	reversed	if	targeted	with	




has	 been	 proposed	 that	 upcoming	 therapeutic	 interventions	 should	 be	 multifactorial	 in	
nature	 and	 target	multiple	 elements	 of	 the	 secondary	 injury	 cascade	 (Vink	 and	 Van	 Den	





It	 has	 been	 consistently	 demonstrated	 that	 the	 amyloid	 precursor	 protein	 (APP)	 and	 its	
derivatives	are	neuroprotective	following	experimental	TBI	(Thornton	et	al.,	2006,	Corrigan	
et	 al.,	 2011,	 Corrigan	 et	 al.,	 2012b,	 Corrigan	 et	 al.,	 2012a,	 Corrigan	 et	 al.,	 2014).	
Intracerebroventricular	 administration	 of	 APP	 was	 shown	 to	 ameliorate	 both	 motor	 and	
cognitive	deficits,	as	well	as	attenuate	cellular	 loss	and	 inflammation	following	TBI	 in	vivo.	
This	makes	APP	a	promising	candidate	to	develop	as	a	therapeutic	treatment	for	TBI	patients.	
APP	 undergoes	 distinct	 proteolytic	 events	 (Andrew	 et	 al.,	 2016),	 and	 the	 soluble	 APPa	
(sAPPa)	species,	produced	via	proteolytic	cleavage	with	a secretase	enzyme,	is	thought	to	be	
responsible	for	APP’s	neuroprotective	properties	following	TBI,	including	protection	against	
a	 range	 of	 cytotoxic	 insults,	 regulation	 of	 neurite	 outgrowth	 and	 synaptogenesis,	 and	
improvement	 in	 functional	 outcome	 in	 vivo	 (Bayer	 et	 al.,	 1999,	Dawkins	 and	 Small,	 2014,	
Plummer	et	al.,	2016).		
	
Domain	mapping	 studies	 attributed	 the	 neuroprotective	 activity	 of	 sAPPa	 to	 the	 growth	
factor	 domains	 (Corrigan	 et	 al.,	 2011),	with	 subsequent	 sequence	 activity	 studies	 able	 to	
localize	the	neuroprotective	activity	to	the	N terminal	heparin	binding	region,	encompassed	
by	 amino	 acid	 residues	 96 110	 (Corrigan	 et	 al.,	 2014).	 It	 was	 shown	 that	 APP96 110’s	
neuroprotective	activity	correlated	with	its	affinity	for	heparin	(Clarris	et	al.,	1997,	Corrigan	
et	al.,	2011,	Corrigan	et	al.,	2014).	Intracerebroventricular	administration	of	APP96 110	was	











APP96 110,	 along	 with	 its	 therapeutic	 window,	 following	 moderate severe	 diffuse	 TBI.	
APP96 110	was	firstly	administered	IV	at	30	minutes	after	trauma,	and	its	effects	on	motor	
outcome,	 the	 extent	 of	 DAI	 and	 neuroinflammation	 at	 3	 days	 were	 assessed.	 Secondly,	

























housed	 in	 a	 controlled	 temperature	 environment	 under	 a	 12	 hour	 light/dark	 cycle,	 with	






severe,	 and	 its	 heterogeneity	 provides	 a	 clinically	 relevant	model	 to	 test	 neuroprotective	






directly	 after	 injury	whilst	 introducing	 a	 period	 of	 post traumatic	 hypoxia	with	 2L/min	 of	
nitrogen	and	0.2L/min	of	oxygen	 (Hellewell	et	al.,	2010).	Post traumatic	hypoxia	has	been	
previously	shown	to	exacerbate	both	AI	and	 inflammation,	and	can	often	be	attributed	to	











their	home	cage	 to	 recover	once	normal	behaviour	was	established.	 Intensive	 continuous	
monitoring	of	the	animals	was	provided	for	the	first	2	hours	post procedure	and	animals	were	
then	 checked	 at	 least	 hourly	 for	 the	 next	 4	 hours.	 If	 signs	 of	 clinical	 deterioration	 were	
evident,	 the	 frequency	 of	 monitoring	 was	 adjusted	 accordingly	 so	 that	 appropriate	
intervention	could	occur.	Following	 this	 initial	period,	animals	were	monitored	 twice	daily	
with	 clinical	 record	 sheets	 maintained	 to	 assess	 the	 following	 criteria:	 daily	 weight	 loss,	
appearance	and	texture	of	their	coats,	posture,	changes	in	social	behaviour,	as	well	as	the	
presence	or	absence	of	stress	marks,	circling	behaviour,	operation	site	swelling,	and	paresis.	
Weight	 loss	 of	 greater	 than	 5 10%	 of	 their	 pre surgical	 body	 weight	 were	 treated	 with	























serial	 sections.	 Immunohistochemistry	 was	 performed	 following	 standard	 procedure	with	
sections	stained	for	APP	for	axonal	 injury	(22C11;	Boéhringer,	1:1000),	glial	 fibrillary	acidic	
protein	(GFAP;	Dako,	1:40,000)	and	 Iba1	(Wako,	1:10,000).	Following	overnight	 incubation	
with	 the	 primary	 antibody,	 slides	 were	 then	 incubated	 with	 the	 appropriate	 secondary	
antibody	 (1:250,	Vector),	before	 incubation	with	 streptavidin	peroxidase	conjugate	 (SPC	–	
1:1000).	 This	 was	 followed	 by	 antigen	 detection	 with	 3,3' Diaminobenzidine	
tetrahydrochloride	 (DAB)	 for	 7	 minutes,	 and	 sections	 counterstained	 with	 haematoxylin.	
Sections	 were	 digitally	 scanned	 using	 the	 Nanozoomer	 slide	 scanner	 (Hamamatsu,	
Hamamatusu	City,	Shizuoka,	Japan),	and	the	associated	software	(NDPview)	used	to	view	and	






and	was	 chosen	 as	 this	 region	has	previously	 demonstrated	 the	highest	 degree	of	 axonal	
injury.		
	
GFAP	 and	 Iba1	 immunoreactivity	 was	 determined	 by	 assessing	 morphology	 (previously	
described	 in	Materials	&	Methods	 Part	 I,	 sections	 2.6.2	&	 2.6.3).	 The	 number	 of	 reactive	








A	 total	 of	 40	 adult	 male	 Sprague Dawley	 rats	 weighing	 between	 361g	 and	 427g	 were	
randomly	 assigned	 into	 3	 day	 sham,	 vehicle	 control,	 0.05mg/kg	 and	 0.5mg/kg	APP96 110	
treatment	 groups.	 The	 APP96 110	 peptide	 was	 manufactured	 as	 described	 above,	 and	
animals	were	again	injured	using	the	impact acceleration	model	of	diffuse	TBI	as	described	
above	 (Marmarou	 et	 al.,	 1994).	 4	 animals	 died	 shortly	 following	 the	 trauma,	 with	 the	
remaining	 animals	 monitored	 appropriately	 in	 accordance	 with	 ethical	 guidelines	 as	
previously	 described.	 Sham	 animals	 were	 surgically	 prepared	 but	 not	 injured.	 At	 5	 hours	
following	TBI,	animals	were	administered	either	saline,	0.05mg/kg	or	0.5mg/kg	APP96 110	
intravenously	via	the	tail	vein	by	a	blinded	observer,	before	being	returned	to	their	home	
























days	 1	 to	 4	 post injury	 (p<0.05).	 However,	 treatment	 with	 both	 0.05mg/kg	 (n=9)	 and	
0.5mg/kg	 (n=7)	 APP96 110	 improved	motor	 outcome	 over	 7	 days,	 as	 these	 animals	 only	



















immunoreactivity	 (170±9	 and	 172±6,	 respectively),	 compared	 to	 vehicle	 control	 animals	
(p<0.001),	with	levels	similar	to	that	seen	in	shams.		
	
These	 astrocytic	 changes	 were	 mirrored	 by	 Iba1	 immunoreactivity	 (Figure	 4.4)	 where	 a	
significant	increase	in	the	number	of	microglia	was	observed	in	the	corpus	callosum	of	vehicle	
control	 animals	 (127±7,	 n=5)	 at	 3	 days	 post TBI	when	 compared	 to	 sham	 animals	 (85±4,	
p<0.01,	n=4).	Notably,	animals	treated	with	both	the	0.05mg/kg	(n=5)	and	0.5mg/kg	(n=4)	
doses	of	APP96 110	also	demonstrated	a	return	to	sham	level,	with	significant	reductions	in	





















shams	on	all	3	assessment	days	 (p<0.001,	n=9).	 In	contrast,	 treatment	with	both	doses	of	
APPP96 110	significantly	improved	motor	ability.	Animals	treated	with	0.05mg/kg	APP96 110	












neuroprotective	 role	 following	 TBI	 (Van	 den	 Heuvel	 et	 al.,	 1999,	 Thornton	 et	 al.,	 2006,	
Corrigan	 et	 al.,	 2011,	 Corrigan	 et	 al.,	 2012b).	 This	 study	 is	 the	 first	 to	 examine	 the	
neuroprotective	efficacy	of	APP96 110	following	IV	administration	after	TBI.		
	
Posttraumatic	 administration	 of	 APP96 110	 IV	 not	 only	 demonstrated	 noticeable	
improvements	 in	 motor	 outcome	 and	 reductions	 in	 AI	 and	 neuroinflammation,	 but	




into	the	brain	parenchyma	as	early	as	15	minutes	after	 injury,	 lasting	for	up	to	 four	to	six	
hours	for	large	molecules.	Permeability	for	smaller	molecules,	however,	can	last	up	to	three	
to	 four	 days	 (Baskaya	 et	 al.,	 1997,	 Habgood	 et	 al.,	 2007).	 Whilst	 this	 permeability	 does	
contribute	 to	 the	 injury	 process,	 it	 also	 provides	 a	window	of	 opportunity	 through	which	
therapeutics	may	gain	entry	to	the	brain	(Habgood	et	al.,	2007).	A	challenge	for	many	IV	drugs	
targeting	brain	injury	is	the	inability	to	penetrate	the	BBB	and	reach	the	CNS.	However,	the	
ability	of	 IV	administered	APP96 110	to	produce	neuroprotective	effects	 in	vivo	 that	were	
comparable	to	intracerebroventricular	administration,	suggests	that	APP96 110	can	enter	the	
brain	following	injury	in	a	functional	state	via	the	IV	route.	This	has	been	confirmed	by	out	









post TBI	 (Vink	and	Van	Den	Heuvel,	 2004,	 Faden	and	Stoica,	 2007).	However,	 in	 a	 clinical	
setting,	the	time	frame	between	injury	and	arrival	to	a	trauma	unit	can	often	far	exceed	one	










treated	with	 the	 higher	 doses	 no	 longer	 displayed	 significant	motor	 deficits	 compared	 to	
shams	 at	 two	 days	 after	 TBI.	 	Moreover,	 these	 doses	 were	 able	 to	 reduce	 the	 currently	
untreatable	DAI,	with	the	0.05mg/kg	dose	of	APP96 110	producing	a	significant	decrease	in	
DAI	compared	to	vehicle	control	animals	at	3	days	post TBI.	 Importantly,	when	APP96 110	
was	 administered	 at	 5	 hours	 following	 injury,	 both	 the	 0.05mg/kg	 and	 0.5mg/kg	 doses	




associated	 with	 a	 reduction	 in	 levels	 of	 DAI	 in	 the	 corpus	 callosum	 at	 day	 3	 post injury	
compared	to	vehicle	control	animals.	DAI	occurs	as	a	result	of	a	progressive	secondary	insult	
to	axons,	often	leading	to	prolonged	neurological	damage	(Heath	and	Vink,	1999,	Povlishock,	
1993,	 Maxwell	 et	 al.,	 1993).	 Primary	 injury	 often	 causes	 considerable	 axonal	 stretching,	
causing	 localized	 damage	 to	 the	 cytoskeleton	 and	 subsequent	 disruption	 to	 axoplasmic	
transport.	 However,	 much	 of	 the	 progression	 of	 DAI	 is	 secondary	 in	 nature,	 with	 the	
disruption	 of	 axoplasmic	 transport	 leading	 to	 axonal	 swelling	 and	 subsequent	 axonal	
disconnection	(Povlishock,	1993,	Buki	and	Povlishock,	2006),	 the	disruption	of	sodium	and	
calcium	 channels	 facilitating	 an	 influx	 of	 ions,	 and	 the	 production	 of	 deleterious	










the	 sole	 factor.	 A	 hallmark	 feature	 of	 TBI	 is	 neuroinflammation,	 a	 significant	 part	 of	 the	
secondary	injury	cascade,	which	often	leads	to	the	prolonged	and	detrimental	neurological	




beneficial	 and	 detrimental	 functions	 following	 CNS	 injury,	 including	 the	 release	 of	
neurotrophic	factors,	but	also	both	pro 	and	anti inflammatory	cytokines	(Kumar	and	Loane,	
2012).	The	 impact acceleration	model	of	diffuse	TBI	produces	wide spread	axonal	damage	
throughout	 the	brain,	 particularly	 in	white	matter	 tracts,	 like	 the	 corpus	 callosum,	where	
axons	 are	 abundant	 (Marmarou	 et	 al.,	 1994).	 Whilst	 neuroinflammation	 can	 often	 be	
observed	in	cortical	regions,	in	this	setting	it	was	assessed	within	the	corpus	callosum,	as	this	
region	 corresponds	 to	 the	 largest	 area	 of	 damage	 seen	 following	 diffuse	 trauma.	
Administration	 of	 APP96 110	 at	 30	 minutes	 post TBI	 prevented	 the	 profound	
neuroinflammation	associated	with	TBI	at	all	doses	 tested,	with	numbers	of	both	 reactive	




injury	 and	 DAI	 was	 more	 considerable.	 Furthermore,	 the	 reduction	 in	 acute	
neuroinflammation	 could	 represent	 a	 pathway	 in	 which	 APP96 110	 treatment	 acts	 to	
ameliorate	the	motor	deficits.	As	animals	were	assessed	at	day	3,	these	results	only	represent	
the	 acute	 neuroinflammatory	 response,	 and	 as	 such	 are	 not	 reflective	 of	 the	 long term	












heparin	 binding	 for	 its	 neuroprotective	 activity	 was	 demonstrated	 using	 an	 APP96 110	
analogue	with	 reduced	heparin	binding	affinity,	which	 in	 turn	showed	no	neuroprotective	
effect	 in	 vivo	 after	moderate severe	 diffuse	 TBI	 (Corrigan	 et	 al.,	 2014).	 It	 is	 thought	 that	









a	 novel	 and	 multifactorial	 therapeutic	 agent	 following	 trauma.	 Important	 next	 steps	 for	
APP96 110	 include	 enhancing	 our	 understanding	 of	 its	 pharmacokinetics	 to	 optimize	 its	
therapeutic	activity,	and	also	identifying	its	receptor	and	the	signaling	pathways	it	activates,	
























Corrigan	et	al.,	 2011,	Corrigan	et	al.,	 2012b,	Corrigan	et	al.,	 2012a,	Corrigan	et	al.,	 2014).	
APP96 110,	in	particular,	has	been	shown	to	provide	efficacy	in	both	APP	knockout	( / )	mice	
and	in	rats	following	diffuse	TBI,	observed	through	the	restoration	of	functional	deficits,	the	
preservation	of	cortical	and	hippocampal	tissue,	as	well	as	reductions	in	axonal	injury	in	the	
corpus	 callosum	 (Corrigan	 et	 al.,	 2014).	 Furthermore,	 its	 neuroprotective	 ability	 has	 since	
been	shown	to	extend	for	up	to	5	hours	post TBI,	with	intravenous	administration	shown	to	
continue	 to	 improve	 motor	 outcome	 for	 up	 to	 7	 days,	 and	 reduce	 axonal	 injury	 and	
neuroinflammation	(results	previously	discussed	in	chapter	4).	
	
Over	 recent	 years,	 these	 neuroprotective	 actions	 of	 APP96 110	 have	 gradually	 been	
attributed	 to	 two	 of	 APP’s	 functional	 domains	 (Corrigan	 et	 al.,	 2011).	 The	 D1	 domain	 in	











the	neuroprotective	activity	of	APP96 110	seems	to	correlate	to	 its	ability	 to	bind	heparin	
(Clarris	et	al.,	1997,	Corrigan	et	al.,	2011,	Corrigan	et	al.,	2014).			
		
Accordingly,	 the	 modulation	 of	 the	 heparin	 binding	 affinity	 of	 APP96 110	 may	 prove	
beneficial	in	an	attempt	to	increase	its	neuroprotective	action.	As	such,	this	study	aimed	to	
examine	whether	mutation	 of	 key	 amino	 acid	 residues	 on	 APP96 110	would	 result	 in	 an	
increased	 binding	 affinity	 to	 heparin,	 and	 subsequently	 confer	 greater	 neuroprotective	
efficacy	post TBI	in	vivo.	Wildtype	(WT)	APP96 110	was	assessed	against	two	mutated	APP96
110	 peptides	with	 either	 two	 or	 three	 amino	 acid	mutations,	 and	 their	 ability	 to	 bind	 to	
heparin	assessed	via	chromatography	assay.	Secondly,	the	peptide	with	the	strongest	affinity	
for	 heparin	was	 then	 assessed	 in	 vivo	 following	 TBI,	 to	 determine	whether	 the	 enhanced	



























(GE	 Healthcare,	 Sydney,	 NSW,	 Australia),	 equilibrated	 in	 Buffer	 A	 (20mM	 Tris	 7.5)	 and	









Prior	 to	 injury,	 each	 peptide	 was	 dissolved	 into	 distilled	 water	 to	 produce	 a	 1mM	 stock	
solution,	and	further	diluted	to	produce	doses	of	0.5mg/kg	and	0.05mg/kg	WT	APP96 110,	






housed	 in	 a	 controlled	 temperature	 environment	 under	 a	 12	 hour	 light/dark	 cycle,	 with	
uninterrupted	access	to	food	and	water.	Animals	were	randomly	assigned	into	3	day	sham,	
vehicle	control,	0.05mg/kg	or	0.5mg/kg	WT	APP96 110,	or	0.05mg/kg,	0.1mg/kg,	0.25mg/kg	
or	 0.5mg/kg	 3+APP96 110	 treatment	 groups.	 Animals	 were	 injured	 using	 the	 Marmarou	
impact acceleration	model	of	diffuse	TBI	 (Marmarou	et	 al.,	 1994)	 (previously	described	 in	
Materials	 &	 Methods	 Part	 I,	 section	 2.3.2).	 At	 5	 hours	 following	 TBI,	 animals	 were	
administered	 either	 saline	 vehicle	 control,	 0.05mg/kg	 or	 0.5mg/kg	 WT	 APP96 110,	 or	
0.05mg/kg,	0.1mg/kg,	0.25mgkg	or	0.5mg/kg	3+APP96 110	IV	via	the	tail	vein	by	a	blinded	
































Given	 the	 stronger	 heparin	 binding	 affinity	 displayed	 by	 3+APP96 110	 over	 the	 other	
analogue	 (2+APP96 110),	 this	 peptide	 was	 assessed	 in	 vivo	 following	 TBI,	 to	 determine	














on	 day	 1	 post TBI	 (p<0.001).	 Animals	 treated	 with	 mutated	 3+APP96 110	 demonstrated	
variable	improvements	in	motor	outcome.	Animals	treated	with	the	highest	dose	of	3+APP96
110	 (0.5mg/kg)	 demonstrated	 no	 improvement	 in	 motor	 outcome,	 with	 animals	 not	
significantly	differently	from	vehicles,	but	were	significantly	different	to	shams	on	all	3	days	
post TBI	 (p<0.001),	 and	 significantly	different	 to	WT	APP96 110	0.5mg/kg	 treated	animals	










however,	 there	 were	 no	 significant	 differences	 observed	 between	 WT	 APP96 110	 and	
3+APP96 110	doses,	when	compared	to	vehicle	control	rats.	
	
Firstly,	 when	 assessing	 the	 WT	 APP96 110,	 treatment	 with	 0.05mg/kg	 WT	 APP96 110	
demonstrated	reductions	in	Ai	compared	to	vehicle	control	rats	(32.9±11.47,	n=6),	however	
this	 was	 not	 significant	 (p=0.99).	 Furthermore,	 treatment	 with	 0.5mg/kg	 WT	 APP96 110	
demonstrated	 significant	 increases	 in	 the	 extent	 of	 AI	 compared	 to	 sham	 animals	
(39.83±11.09,	n=7)	(p=0.02).		
	























heparin.	 When	 assessed	 in	 vivo	 following	 TBI,	 these	 peptides	 demonstrated	 a	 dose
dependent	 improvement	 in	 motor	 outcome,	 with	 lower	 doses	 of	 the	 enhanced	 peptide	
improving	 motor	 outcome	 equal	 to	 higher	 doses	 of	 the	 wildtype	 peptide.	 These	
improvements	 in	 outcome	were	 associated	with	 variable	 decreases	 in	 AI	 throughout	 the	
corpus	 callosum,	 predominantly	 following	 treatment	 with	 the	 0.1mg/kg	 and	 0.25mg/kg	
3+APP96 110	doses.		
	
The	 ability	 to	 selectively	 mutate	 a	 protein	 based	 on	 its	 amino	 acid	 sequence,	 and	
subsequently	design	and	generate	analogues	 to	APP96 110	 is	an	exciting	prospect	 for	 the	









at	 650mM	 and	 3+APP96 110	 possessing	 greater	 affinity	 and	 eluting	 at	 750mM,	 when	





the	 initial	step	 in	exploring	the	‘heparin	binding	hypothesis’,	 it	was	crucial	to	establish	the	
efficacy	of	these	peptides	 in	an	 in	vivo	TBI	model.	Animals	treated	with	both	doses	of	WT	
APP96 110	demonstrated	considerable	improvements	in	motor	outcome	post TBI	compared	
to	 vehicle	 control	 rats,	which	 is	 in	 line	with	 previous	 our	 findings	 (Thornton	 et	 al.,	 2006,	
Corrigan	et	al.,	2012b,	Corrigan	et	al.,	2014)	(results	previously	described	in	Chapter	4).	The	
enhancement	 of	 heparin	 binding	 affinity	 in	 the	 APP96 110	peptide	 produced	widespread	
improvement	of	motor	performance.	Rats	treated	with	0.25mg/kg	of	mutated	3+APP96 110	
showed	 significantly	 improved	 motor	 performance	 post TBI	 when	 compared	 to	 vehicle	




not	 entirely	 mirrored	 following	 histological	 examination	 of	 AI.	 Only	 selective	 doses	 of	
3+APP96 110,	 the	 0.25mg/kg	 and	 0.1mg/kg	 3+APP96 110	 doses,	 were	 able	 to	 reduce	 AI	
compared	 to	 vehicle	 control	 animals.	Unexpectedly,	 treatment	with	 the	highest	0.5mg/kg	





sample	 size	 in	 this	 group	 (n=3)	 compared	 to	 the	 other	 groups	 (n=6)	 may	 explain	 the	
substantial	 lack	 of	 neuroprotective	 efficacy	 of	 this	 dose,	 and	 suggests	 that	 a	 therapeutic	
threshold	has	been	reached,	beyond	which	any	neuroprotective	benefits	can	be	achieved.	
Overall,	 these	 motor	 and	 histological	 observations	 indicate	 the	 ability	 of	 the	 mutated	
3+APP96 110	 peptides	 to	 improve	 motor	 outcome	 and	 reduce	 AI	 occurring	 in	 a	 dose
dependent	 fashion,	with	 lower	 doses	 of	mutated	 3+APP96 110	 peptides	 conferring	 equal	
neuroprotective	efficacy	compared	to	higher	doses	of	WT	APP96 110.	This	may	be	through	
its	 enhanced	 ability	 to	 bind	 to	 heparin,	 and	 lends	 further	 weight	 to	 the	 heparin	 binding	
hypothesis	for	its	mechanism	of	action.	
	
Taken	together,	 the	findings	of	 this	study	support	heparin	binding	activity	being	at	 least	a	
strong	correlate	of	APP96 110’s	neuroprotective	activity,	and	a	number	of	studies	over	recent	
decades	 have	 suggested	 this.	 The	 structure	 of	 APP96 110	 contains	 a	 β	 hairpin	 loop	
constrained	by	a	disulphide	bond	between	cysteines	98	and	105	(Rossjohn	et	al.,	1999,	Small	
et	 al.,	 1994),	 the	 presence	 of	which	 has	 been	 shown	 to	 be	 critical	 for	 promoting	 neurite	
outgrowth	from	central	and	peripheral	neurons	(Young Pearse	et	al.,	2008),	as	well	as	the	
activation	of	MAP	kinase	(Greenberg	and	Kosik,	1995).	Indeed,	the	binding	of	this	region	to	
HSPGs	 can	promote	neurite	 outgrowth	 from	 central	 and	peripheral	 neurons	 (Small	 et	 al.,	
1994,	Williamson	et	al.,	1995,	Williamson	et	al.,	1996).	Further	evidence	has	shown	that	the	
D1	 domain	 of	 sAPPa,	 of	 which	 APP96 110	 is	 the	 active	 region,	 displays	 a	 high	 structural	
similarity	to	growth factor	like domains,	and	exhibits	a	strong	affinity	to	heparin,	particularly	










which	 are	 important	 steps	 in	 promoting	 neuroplasticity	 and	 subsequent	 neurogenesis	










to	 generate	 analogues	 with	 an	 increased	 affinity	 for	 heparin	 can	 result	 in	 increased	
neuroprotective	 action	of	 these	peptides	 in	 vivo	 following	TBI.	 Results	 suggest	 that	 lower	
doses	of	mutated	3+APP96 110	may	confer	equal	neuroprotective	efficacy	to	higher	doses	of	
WT	 APP96 110,	 with	 this	 finding	 potentially	 having	 considerable	 impacts	 from	 both	 a	
manufacturing	and	clinical	viewpoint.	In	deciding	upon	the	most	efficacious	dose	of	either	WT	




dose	 ultimately	 chosen	 due	 to	 its	 ability	 to	 improve	motor	 outcome,	 and	 the	 associated	
decrease	in	AI	compared	to	vehicle	control	animals.	The	observations	that	the	enhancement	













The	 Amyloid	 Precursor	 Protein	 (APP)	 and	 its	 various	 derivatives	 like	 APP96 110	 have	
consistently	 demonstrated	 neuroprotective	 efficacy	 when	 administered	 following	
experimental	TBI	(Van	den	Heuvel	et	al.,	1999,	Thornton	et	al.,	2006,	Corrigan	et	al.,	2011,	
Corrigan	et	al.,	2012b,	Corrigan	et	al.,	2012a,	Corrigan	et	al.,	2014).	This	efficacy	has	been	







APP96 110	 sequence	 has	 been	 shown	 to	 enhance	 its	 heparin	 binding	 affinity	 (previously	
discussed	 in	 Chapter	 5),	 and	 following	 in	 vivo	 administration	 post TBI,	 resulted	 in	 greater	
neuroprotective	action	compared	to	WT	APP96 110.	In	particular,	treatment	with	0.25mg/kg	
3+APP96 110	appeared	to	confer	equal	neuroprotective	activity	compared	to	0.5mg/kg	WT	
























For	 this	 study,	 two	 APP96 110	 peptides	were	 used:	WT	APP96 110	 and	 3+APP96 110.	 As	
previously	 outlined	 in	 Materials	 &	 Methods	 part	 I,	 section	 2.3.3	 the	 APP	 peptides	 were	
custom	 synthesized	 by	Auspep	 (Tullamarine,	 Victoria,	 Australia)	 and	were	 all	N terminally	

















housed	 in	 a	 controlled	 temperature	 environment	 under	 a	 12	 hour	 light/dark	 cycle,	 with	
uninterrupted	access	to	food	and	water.	Animals	were	randomly	assigned	into	24	hour	or	30	
day	outcome	groups,	and	each	further	assigned	 into	sham,	vehicle	control,	0.25mg/kg	WT	
APP96 110	or	 0.25mg/kg	 3+APP96 110	 treatment	 groups.	Animals	were	 injured	using	 the	
Marmarou	 impact acceleration	 model	 of	 diffuse	 TBI	 (Marmarou	 et	 al.,	 1994)	 (previously	
described	 in	 Materials	 &	 methods	 Part	 1,	 section	 2.3.2).	 Sham	 animals	 were	 surgically	
prepared	but	not	injured	and	did	not	receive	hypoxia.	At	5	hours	following	TBI,	animals	were	





























described	 in	 detail	 in	 Materials	 &	 Methods	 Part	 I,	 sections	 2.5.1	 &	 2.5.2,	 respectively).		
Formalin	fixed	tissue	was	prepared	accordingly	for	IHC	analysis	with	the	following	antibodies:	












SEM	 with	 a	 significance	 level	 of	 p<0.05.	 Motor	 outcome	 was	 assessed	 using	 a	 two way	











Motor	outcome	was	assessed	using	 the	 rotarod	 (Figure	6.1).	 Sham	animals	demonstrated	
normal	motor	abilities	over	the	testing	period,	recording	a	120	seconds	on	all	days	post TBI.	
In	contrast,	vehicle	treated	animals	demonstrated	significant	motor	deficits	on	all	3	days	post	
TBI	 (p<0.01),	 returning	 to	 a	 score	 of	 108	 seconds	 by	 7	 days	 post	 injury,	 and	maintaining	
around	 this	 level	 of	 performance	 for	 the	 rest	 of	 the	 testing	 period.	 Rats	 treated	 with	
0.25mg/kg	WT	APP96 110	showed	significant	differences	compared	to	sham	animals	on	all	3	
days	post TBI	(p<0.05),	with	no	differences	compared	to	vehicle	control	treated	animals.	In	















































significant	 impairments	 in	 their	ability	 to	 locate	the	escape	box	 (84.4±8.79,	p<0.01),	when	
compared	to	sham	animals	(51.4±8.79).	Rats	treated	with	0.25mg/kg	WT	APP96 110	showed	
a	reduced	amount	to	time	required	to	locate	the	escape	box,	averaging	68.7±8.5	seconds.	In	
contrast,	 animals	 treated	with	0.25mg/kg	3+APP96 110	displayed	 similar	 abilities	 to	 sham	
rats,	averaging	47.9±8.79	seconds	to	locate	the	escape	box,	performing	significantly	different	










animals	 taking	 2.6±4.5	 seconds	 (p=0.068),	 respectively.	 No	 significant	 differences	 were	
observed	between	treatment	groups	in	the	time	it	took	for	animals	to	find	the	location	of	the	
new	escape	box	over	two	trials	(p=0.26).	In	the	first	trial,	vehicle	control	animals	averaged	















No	 significant	 differences	were	 noted	 in	 the	 percentage	 of	 activated	microglia	within	 the	
cortex	(p=0.73).	Sham	animals	had	a	percentage	of	25.19±3.05%	activated	microglia,	vehicle	
control	 animals	 27.96±3.05%,	 0.25mg/kg	 WT	 APP96 110	 27.12±2.875%	 and	 0.25mg/kg	
3+APP96 110	 25.03±3.05%.	 However,	 in	 the	 corpus	 callosum	 there	 were	 significantly	
different	 numbers	 of	 activated	 microglia	 (p=0.027).	 Here,	 vehicle	 control	 animals	











The	 absolute	 number	 of	 reactive	 astrocytes	 in	 the	 cortex	 and	 the	 corpus	 callosum	were	
assessed	using	a	GFAP	antibody	(previously	described	in	Materials	&	Methods	Part	I,	section	
2.6.3).	No	significant	differences	in	the	absolute	number	of	reactive	astrocytes	were	observed	
between	 any	 of	 the	 treatment	 groups	 in	 either	 the	 cortex	 or	 corpus	 callosum	at	 30	 days	
following	TBI	(p=0.28,	p=0.92,	Figure	6.6).		In	the	cortex,	sham	animals	had	a	higher	number	
of	GFAP+	cells	(50.73±6.754),	compared	to	vehicle	control	animals	(41.5±6.754),	whilst	WT	
APP96 110	 and	 3+APP96 120	 treated	 animals	 demonstrated	 similar	 numbers	 shams	
(40.43±6.368	and	38.42±7.754	GFAP+ve	cells,	respectively).	Within	the	corpus	callosum,	all	
animals	 had	 similar	 numbers	 of	 GFAP+ve	 cells,	 with	 shams	 demonstrating	 217.1±26.47,	














PSD 95	 is	a	post synaptic	scaffolding	protein	used	to	examine	the	post synaptic	density	of	
neurons	 following	TBI	 (Figure	6.7).	No	significant	differences	were	noted	within	either	the	
cortex	 (p=0.57),	 or	 hippocampus	 (p=0.35).	 However,	 within	 the	 cortex,	 vehicle	 control	




vehicle	 control	 animals	 demonstrated	 no	 differences	 in	 PSD 95	 relative	 density	
(25075±3115),	 compared	 to	 sham	 animals	 (25294±3115).	 In	 contrast,	 treatment	 with	
0.25mg/kg	 WT	 APP96 110	 reduced	 the	 PSD 95	 relative	 density	 to	 20889±3115,	 while	












Until	 this	 point,	 research	 assessing	 the	 neuroprotective	 efficacy	 of	 APP96 110	 peptides	
following	TBI	has	only	been	assessed	acutely	following	trauma.	As	such,	this	is	the	first	study	
to	examine	the	long term	efficacy	of	IV	APP96 110	derivatives	following	TBI,	and	forms	the	
logical	 next	 step	 in	 the	 progression	 and	 development	 of	 APP96 110	 derivatives	 as	 novel	
therapeutic	agents	following	TBI.		
	
Treatment	 with	 the	 enhanced	 0.25mg/kg	 3+APP96 110	 peptide	 resulted	 in	 significant	
improvements	in	motor	outcome	early,	with	animals	returning	to	sham	level	by	day	5	and	
maintained	 this	 level	 throughout	 the	 30	 day	 testing	 period.	 Importantly,	 treatment	 with	
either	WT	or	3+APP96 110	did	not	produce	any	physical	signs	of	long term	toxicity	over	30	
days.	 The	 3+APP966 10	peptide	 also	 produced	 significant	 effects	 in	 learning	 and	memory	
ability	of	the	rats.	This	was	associated	with	a	significant	reduction	in	microglial	activation	in	
the	corpus	callosum	with	WT	APP96 110	treatment,	with	a	trend	towards	significance	with	
the	 3+APP96 110	 treatment.	 However,	 no	 changes	 in	 astrocyte	 reactivity	were	 observed.	
Overall	 there	 were	 no	 significant	 differences	 between	 treatment	 groups	 following	
examination	of	the	relative	expression	of	proteins	related	to	changes	to	synapses,	dendrites,	












While	 there	were	no	 significant	differences	 in	motor	outcome	between	 treatment	groups	
beyond	14	days	post TBI,	continuous	observation	over	the	30	day	timepoint	did	not	highlight	
any	 long term	 changes	 in	 motor	 performance,	 with	 animals’	 performance	 remaining	




administration	 of	 APP96 110	 up	 to	 5	 hours	 post TBI	 may	 be	 sufficient	 to	 exert	 its	



























Maze,	 vehicle	 control	 animals	 did	 not	 display	 the	 levels	 of	 anxiety	 anticipated	 in	 injured	
animals.	 A	 lack	 of	 anxiety	 6	 weeks	 following	 TBI	 has	 been	 noted	 previously,	 with	 rats	
displaying	memory	disruptions,	but	a	lack	of	anxiety,	as	assessed	with	this	maze,	following	
focal	 TBI	 at	 a	 similar	 age	 to	 the	 rats	 used	 in	 this	 study	 (Amoros Aguilar	 et	 al.,	 2015).	
Consequently,	no	conclusions	about	the	effect	of	treatment	on	 long term	anxiety	post TBI	
could	be	drawn.	While	 the	mazes	chosen	are	all	well established	 for	 rodent	cognitive	and	




















































and	 synapses,	 axonal	 structure	 and	 the	 beginnings	 of	 neurodegeneration	 through	 tau	
proteins.	 With	 the	 exception	 of	 0.25mg/kg	 WT	 APP966 10	 significantly	 increasing	 the	








in depth	 investigation	 is	 warranted.	 The	 lack	 of	 differences	 observed	 in	 both	 total	 and	
phosphorylated	tau	suggests	in	part,	that	the	30	day	time point	may	be	too	early	to	look	in
depth	at	long term	neurodegeneration	following	APP966 110	treatment	post TBI.		
	




110	outperformed	WT	APP96 110	 in	 terms	of	 functional	outcome.	Whilst	 the	30	day	time	
point	 in	 this	 study	 may	 lie	 on	 the	 cusp	 of	 displaying	 the	 beginnings	 of	 long term	
neurodegeneration	 and	 neuroinflammation,	 it	 provides	 a	 first	 look	 at	 the	 longer term	
performance	and	outcome	of	rats	following	treatment	with	APP96 110	peptides.	The	novel	
window	of	opportunity	that	exists	between	primary	injury	and	the	initiation	of	the	secondary	
injury	 cascade	 following	 TBI	 provides	 a	 novel	 window	 of	 opportunity	 for	 a	 therapeutic	
intervention	to	be	able	to	halt	the	progression	of	many	of	the	deleterious	secondary	injury	
events	like	chronic	inflammation.	Together,	the	results	of	this	study	lend	weight	to	support	











TBI	 is	 a	 life threatening	 injury,	 and	 yet	 despite	 its	 serious	 nature,	 there	 are	 currently	 no	
effective	therapeutic	agents	to	treat	the	condition.	The	experiments	within	this	thesis	have	
further	consolidated	the	neuroprotective	role	of	the	APP	derivative	APP96 110	following	TBI,	
with	 an	 emphasis	 on	 progressing	 the	 pre clinical	 development	 of	 this	 peptide	 as	 a	 novel	
therapeutic	agent.	As	such,	the	optimal	dose,	route	and	timepoint	of	administration	for	this	
peptide	 was	 determined	 in	 the	 acute	 phase	 post TBI.	 It	 was	 hypothesized	 that	 the	
neuroprotective	properties	of	APP96 110	following	TBI	are	linked	to	its	heparin	binding	sites,	
and	 these	 specific	 regions	 are	 therefore	 responsible	 for	 APP	 protecting	 against	 neuronal	
injury	 and	 improving	 neurological	 outcome	 following	 TBI.	 Accordingly,	 novel	 APP96 110	
analogues	with	 enhanced	 heparin	 binding	 action	were	 developed,	 with	 administration	 of	
these	 analogues	 tested	 for	 efficacy	 of	 improvement	 in	 long term	 outcome,	
neuroinflammation	and	neurodegeneration.		
	
Currently	 following	 TBI,	 patients	 are	 only	 able	 to	 receive	 symptomatic	 relief	 with	
osmotherapies	or	 the	 surgically	 invasive	decompressive	 craniotomy.	To	date,	DAI	 remains	
untreatable,	and	is	the	leading	cause	of	coma	and	vegetative	state	following	TBI	(Smith	et	al.,	
2003,	Adams	et	al.,	1989).	This	highlights	the	need	for	the	development	of	clinically	relevant	
neuroprotective	 therapeutic	 options	 that	 prevent	 the	 ongoing	 damage	 associated	 with	












point	 the	 delayed,	 but	 inevitable,	 secondary	 injury	 events	 like	 cell	 death	 and	




While	 the	 clinical	 relevance	 of	 APP96 110	 as	 a	 potential	 therapy	 for	 TBI	 has	 been	 clearly	
demonstrated,	the	mechanism	of	action	through	which	these	effects	occur	is	yet	to	be	fully	
understood.	The	ability	of	APP96 110	to	have	a	strong	affinity	to	bind	to	heparin	is	currently	






physical	 structure	of	 the	peptide.	Further	evidence	has	highlighted	 that	 the	D1	domain	of	
sAPPa,	of	which	APP96 110	is	the	active	region,	displays	a	high	structural	similarity	to	growth




















enhance	 the	 affinity	 of	 APP96 110	 to	 bind	 to	 heparin.	When	 the	 enhanced	 3+APP96 110	
peptide	was	administered	at	the	same	dose	to	WT	APP96 110	in	vivo	following	TBI,	it	resulted	
in	 greater	 neuroprotective	 action,	 highlighting	 that	 smaller	 doses	 of	 3+APP96 110	 could	
confer	similar	neuroprotective	benefits	to	higher	doses	of	WT	APP96 110	following	trauma.		
	
Up	until	 this	point,	 research	assessing	the	neuroprotective	efficacy	of	APP96 110	peptides	
following	TBI	had	as	only	been	assessed	acutely	following	trauma.	The	ability	of	APP96 110	











produced	 similar	 protection	 for	 neuroinflammation,	 axonal	 structure,	 myelination,	
synaptogenesis	 and	 neurodegeneration,	 treatment	 with	 3+APP96 110	 significantly	
outperformed	WT	APP96 110	in	its	ability	to	improve	functional	outcome.	Whilst	the	30	day	
time	 point	 in	 this	 study	 may	 lie	 on	 the	 cusp	 of	 displaying	 the	 beginnings	 of	 long term	
neurodegeneration	 and	 neuroinflammation,	 it	 provides	 a	 first	 look	 at	 the	 longer term	
performance	and	outcome	of	rats	following	treatment	with	APP96 110	peptides.	The	novel	
window	of	opportunity	that	exists	between	primary	injury	and	the	initiation	of	the	secondary	












in	TBI,	 by	 testing	 the	 response	of	APLP	knockout	 ( / )	mice	 to	TBI,	 assessing	whether	 this	
response	is	gender	dependent,	determining	if	APLP2’s	neuroprotective	activity	is	mediated	
by	 sAPPa,	 and	 examining	 the	 molecular	 and	 cellular	 pathways	 that	 mediate	 the	
neuroprotective	 activity	 of	 sAPPa/APLP2	 in	 TBI.	 The	 second	 grant	 aims	 to	 progress	 this	
important	pre clinical	research	seen	in	this	thesis	 into	an	ovine	model	of	moderate severe	




failed	when	assessed	 in	 the	 clinic,	were	also	 shown	 to	be	 ineffective	 in	 this	 larger	animal	
models	 in	our	 laboratory	 (unpublished	data),	 and	as	 such,	 these	upcoming	 studies	 should	
improve	the	clinical	translation	of	APP96 110.	Due	to	the	gyrencephalic	structure	of	the	sheep	
brain,	 it	 is	 important	 to	 re assess	 the	 therapeutic	 window,	 investigating	 the	 optimal	




this	 peptide	 following	 trauma	 remains.	 Our	 findings	 give	 a	 cursory	 overview	 of	 the	
neuroinflammatory	and	neurodegenerative	 changes	 long term	 following	TBI,	 but	highlight	






antibodies	 like	 tau	 and	a synuclein,	which	 due	 to	 ongoing	 issues	 that	were	 unable	 to	 be	
rectified	in	due	course,	will	be	fully	explored	in	the	near	future.	The	findings	from	this	research	
also	suggest	a	considerable	influence	of	heparin	binding	in	the	mechanism	of	action	of	APP96
110,	 with	 a	 much	 more	 detailed	 investigation	 required	 to	 understand	 this	 fully.	 The	
identification	of	the	receptor,	and	the	subsequent	signaling	pathways	that	this	activates,	will	
help	to	decipher	the	molecular	mechanisms	for	APP96 110’s	activity.	Further	exploration	of	
the	pharmacokinetic	properties	of	APP96 110	 is	 also	vital.	 This	 is	 a	 key	aim	of	one	of	 the	
recently	awarded	NHMRC	grants,	and	will	help	to	further	optimise	the	therapeutic	activity	of	







thesis	 support	 that	 APP96 110	 derivatives	 can	 exert	 their	 neuroprotective	 action	 in	 the	
window	of	opportunity	to	halt	the	progression	of	the	disease,	whilst	also	targeting	multiple	





slow	 the	 progression	 of	 the	 deleterious	 secondary	 injury	 early	 after	 trauma	 to	 minimize	
	 	 	
	 	 138	
functional	 deficits.	 	 Overall,	 APP96 110	 shows	 promise	 as	 a	 novel	 and	 clinically	 relevant	
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Acute	 cytokine	 activity	 in	 the	 hippocampus	 at	 24	 hours	 post TBI	 was	 measured	 using	 a	
milliplex	rat	8 plex	cytokine	kit	(Millipore/Abacus	ALS).	Samples	were	loaded	onto	a	96	well	
plate	in	duplicates,	and	run	in	accordance	to	manufacturer’s	instructions.	The	plate	was	read	
using	 Magpix	 Luminex	 multiplex	 array	 (Abacus ALS,	 Queensland),	 and	 data	 expressed	 as	
pg/ml	of	 concentration.	Experimental	data	was	 calibrated	against	 standard	curves	of	all	 8	
cytokines,	which	were	fitted	using	a	5	parameter	log	fit	through	Analyst	software	(Millipore,	
Australia).	The	values	for	TNFα	fell	below	the	detection	range	and	were	excluded	from	the	





Cytokine	 M1	Vs	M2	Characteristics	 Function	 Brain	Region	Analysed	
Il 1α	 M1	 Pro inflammation	 Left	hippocampus	
IL 1β	 M1	 Pro inflammation	 Left	hippocampus		
IL 4	 M2	 Anti inflammation	 Left	hippocampus		
IL 6	 M1	 Pro inflammation	 Left	hippocampus		
IL 10	 M2	 Anti inflammation	 Left	hippocampus		
IL 12(p70)	 M1	 Anti inflammation	 Left	hippocampus		
IL 13	 M2	 Anti inflammation	 Left	hippocampus		
TNFα	 M1	 Pro inflammation	 Left	hippocampus		

